Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001386570-25-000010
Filing Date
2025-08-06
Accepted
2025-08-06 16:05:06
Documents
65
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cdcx-20250630.htm   iXBRL 10-Q 1577734
2 EX-31.1 nageex-311q22025.htm EX-31.1 10398
3 EX-31.2 nageex-312q22025.htm EX-31.2 10346
4 EX-32.1 nageex-321q22025.htm EX-32.1 5662
10 cdcx-20250630_g1.jpg GRAPHIC 143741
  Complete submission text file 0001386570-25-000010.txt   7526264

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdcx-20250630.xsd EX-101.SCH 39716
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cdcx-20250630_cal.xml EX-101.CAL 53050
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cdcx-20250630_def.xml EX-101.DEF 166777
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cdcx-20250630_lab.xml EX-101.LAB 541861
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cdcx-20250630_pre.xml EX-101.PRE 362138
68 EXTRACTED XBRL INSTANCE DOCUMENT cdcx-20250630_htm.xml XML 1295493
Mailing Address 10900 WILSHIRE BLVD SUITE 600 LOS ANGELES CA 90024
Business Address 10900 WILSHIRE BLVD SUITE 600 LOS ANGELES CA 90024 310-388-6706
Niagen Bioscience, Inc. (Filer) CIK: 0001386570 (see all company filings)

EIN.: 262940963 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37752 | Film No.: 251189449
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)